A Phase 4 interventional study of Pregabalin and Gabapentin in Epilepsy, Partial Seizure Disorder and Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 8 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.
Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 4, and was the 14th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 4
First in 1997; this study’s year is marked. 2 started in 2008.
This study's enrollment of 482 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 244 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 3 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Epilepsies, Partial by Viatris Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 15 (100%) have results posted.
Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2008, is one of 4 in phase 4, and was the 8th registered.
Viatris Inc.’s Epilepsies, Partial studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing pregabalin in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 15 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
This study's enrollment of 482 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Browse Epilepsies, Partial studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pregabalin
Drug: Gabapentin
150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
Percent Change From Baseline in 28-day Seizure Frequency at Week 21.
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure \[SGTC\]).
Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Percentage of Participants With 50% Reduction From Baseline in 28-day Seizure Rate at Week 21.
Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline \<= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no).
Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Percentage of Participants With 75% Reduction From Baseline in 28-day Seizure Rate at Week 21.
Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline \<= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC).
Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Percentage of Participants Without Seizures.
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.
Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Change From Baseline in the 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Frequency at Week 21.
Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline.
Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.
SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate.
Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Hospital Anxiety and Depression Scale (HADS) Score.
HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 21
Medical Outcomes Study Sleep Scale (MOS-SS) Score.
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score \[RS\] minus lowest possible score divided by possible RS range\*100); total score range:0-100; higher score=more intensity of attribute.
Time frame: Baseline, Week 21
Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score.
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.
Time frame: Baseline, Week 21
Overall, 561 participants were screened and 482 participants participated in the study; 242 participants were randomized but one participant from the pregabalin group and one participant from the gabapentin group were not treated. Hence 241 participants were treated in each treatment group. Participants were randomized at 56 centers.
| Milestone | Pregabalin | Gabapentin |
|---|---|---|
| Started | 241 | 241 |
| Completed titration phase | 213 | 210 |
| Completed maintenance phase | 187 | 172 |
| Entered opt blinded continuation phase | 140 | 139 |
| Completed | 58 | 62 |
| Not completed | 183 | 179 |
| Withdrew: Adverse event | 20 | 19 |
| Withdrew: Lack of efficacy | 8 | 16 |
| Withdrew: Lost to follow-up | 23 | 29 |
| Withdrew: Withdrawal by subject | 113 | 95 |
| Withdrew: Protocol violation | 6 | 4 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Study terminated by sponsor | 2 | 3 |
| Withdrew: Other | 10 | 12 |
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure \[SGTC\]).
| percent change | Pregabalin | Gabapentin |
|---|---|---|
| Percent Change From Baseline in 28-day Seizure Frequency at Week 21. | -58.65 (-100.0 to 180.0) | -57.43 (-100.0 to 392.4) |
Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline \<= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no).
| Percentage of participants | Pregabalin | Gabapentin |
|---|---|---|
| All Partial Seizure (n=238, 240) | 56.3 (50.0 to 62.6) | 58.3 (52.1 to 64.6) |
| Simple Partial (n=87, 88) | 55.2 (44.7 to 65.6) | 53.4 (43.0 to 63.8) |
| Complex Partial (n=161, 158) | 56.5 (48.9 to 64.2) | 55.1 (47.3 to 62.8) |
| SGTC (n=112, 114) | 50.9 (41.6 to 60.2) | 60.5 (51.6 to 69.5) |
Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline \<= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC).
| Percentage of participants | Pregabalin | Gabapentin |
|---|---|---|
| All Partial Seizure (n=238, 240) | 33.6 (27.6 to 39.6) | 34.2 (28.2 to 40.2) |
| Simple Partial (n=87, 88) | 36.8 (26.7 to 46.9) | 33.0 (23.1 to 42.8) |
| Complex Partial (n=161, 158) | 37.3 (29.8 to 44.7) | 36.1 (28.6 to 43.6) |
| SGTC (n=112, 114) | 38.4 (29.4 to 47.4) | 43.9 (34.8 to 53.0) |
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.
| percentage of participants | Pregabalin | Gabapentin |
|---|---|---|
| All Partial Seizure (n=189, 182) | 30.7 (24.1 to 37.3) | 34.1 (27.2 to 41.0) |
| Simple Partial (n=74, 66) | 29.7 (19.3 to 40.1) | 36.4 (24.8 to 48.0) |
| Complex Partial (n=126, 123) | 37.3 (28.9 to 45.8) | 40.7 (32.0 to 49.3) |
| SGTC (n=95, 91) | 46.3 (36.3 to 56.3) | 42.9 (32.7 to 53.0) |
Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline.
| percentage of all partial seizure/28days | Pregabalin | Gabapentin |
|---|---|---|
| Baseline (n=114, 114) | 56.53 ± 40.856 | 59.60 ± 40.571 |
| Change from Baseline at Double Blind (n=104, 98) | 1.59 ± 28.164 | -2.17 ± 26.024 |
SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate.
| percentage of responders | Pregabalin | Gabapentin |
|---|---|---|
| Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21. | 30.8 (21.9 to 39.6) | 39.8 (30.1 to 49.5) |
HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| Units on a scale | Pregabalin | Gabapentin |
|---|---|---|
| Baseline HADS-A (n=238, 240) | 7.82 ± 0.31 | 7.60 ± 0.31 |
| HADS- A Change at Week 21/ET (n=212, 210) | -0.92 ± 0.26 | -0.83 ± 0.27 |
| Baseline HADS-D (n=238, 240) | 5.94 ± 0.29 | 5.65 ± 0.29 |
| HADS-D Change at Week 21/ET (n=212, 210) | -0.59 ± 0.24 | -0.42 ± 0.24 |
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score \[RS\] minus lowest possible score divided by possible RS range\*100); total score range:0-100; higher score=more intensity of attribute.
| Units on a scale | Pregabalin | Gabapentin |
|---|---|---|
| Baseline: Sleep Disturbance (n=238, 240) | 29.68 ± 1.70 | 26.43 ± 1.70 |
| Baseline: Snoring (n=238, 240) | 29.28 ± 2.31 | 28.09 ± 2.31 |
| Baseline: Awaken Short of Breath (n=238, 240) | 23.64 ± 2.07 | 19.61 ± 2.07 |
| Baseline: Quantity of Sleep (n=238, 240) | 7.56 ± 0.11 | 7.59 ± 0.11 |
| Baseline: Adequacy of Sleep (n=238, 240) | 61.30 ± 2.01 | 63.67 ± 2.01 |
| Baseline: Somnolence (n=238, 240) | 32.29 ± 1.56 | 29.31 ± 1.56 |
| Baseline: Sleep Problem Index (9) (n=238, 240) | 31.60 ± 1.32 | 28.15 ± 1.32 |
| Week 21: Sleep Disturbance (n=212, 210) | 24.99 ± 1.37 | 25.31 ± 1.39 |
| Week 21: Snoring (n=212, 210) | 28.07 ± 1.89 | 26.12 ± 1.90 |
| Week 21: Awaken Short of Breath (n=212, 210) | 16.26 ± 1.73 | 18.20 ± 1.74 |
| Week 21: Quantity of Sleep (n=212, 210) | 8.79 ± 0.17 | 8.77 ± 0.17 |
| Week 21: Adequacy of Sleep (n=212, 210) | 63.87 ± 1.68 | 64.53 ± 1.69 |
| Week 21: Somnolence (n=212, 210) | 32.04 ± 1.36 | 29.98 ± 1.37 |
| Week 21: Sleep Problem Index (9) (n=212, 210) | 27.88 ± 1.04 | 27.54 ± 1.05 |
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.
| percentage of participants | Pregabalin | Gabapentin |
|---|---|---|
| Baseline (n=238, 240) | 49.2 | 58.8 |
| Week 21 (n=212, 210) | 51.4 | 58.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 13/241 (5.4%) | 77/241 (32%) |
| Gabapentin | — | 14/241 (5.8%) | 77/241 (32%) |
| Event | Pregabalin | Gabapentin |
|---|---|---|
| ConvulsionNervous system disorders | 3/241 | 0/241 |
| PneumoniaInfections and infestations | 2/241 | 0/241 |
| EpilepsyNervous system disorders | 0/241 | 2/241 |
| Status epilepticusNervous system disorders | 0/241 | 2/241 |
| Suicidal ideationPsychiatric disorders | 2/241 | 0/241 |
| Atrial fibrillationCardiac disorders | 1/241 | 0/241 |
| Pericardial effusionCardiac disorders | 1/241 | 0/241 |
| VertigoEar and labyrinth disorders | 0/241 | 1/241 |
| DiplopiaEye disorders | 0/241 | 1/241 |
| Rectal haemorrhageGastrointestinal disorders | 1/241 | 0/241 |
| Event | Pregabalin | Gabapentin |
|---|---|---|
| SomnolenceNervous system disorders | 35/241 | 34/241 |
| HeadacheNervous system disorders | 21/241 | 25/241 |
| Weight increasedInvestigations | 23/241 | 15/241 |
| DizzinessNervous system disorders | 22/241 | 21/241 |
| Dry mouthGastrointestinal disorders | 12/241 | 8/241 |
| Age, Continuous(years) | Pregabalin | Gabapentin | Total |
|---|---|---|---|
| Mean | 34.9 ± 13.0 | 35.3 ± 12.9 | 35.1 ± 13.0 |
| Sex: Female, Male(Participants) | Pregabalin | Gabapentin | Total |
|---|---|---|---|
| Female | 114 | 111 | 225 |
| Male | 127 | 130 | 257 |
The record gives a start of Feb 2008, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Gabapentin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →